Kornimate/medical-research-clean huggingface dataset:
development and evaluation of iwalk: a guide to facilitate evidence-informed assessment of walking after stroke

Conditions: Stroke

Summary: stroke remains a major health concern and the second highest cause of disability worldwide. after experiencing a stroke, many people lose the ability to walk independently. as a result, people with stroke require intensive rehabilitation services, spend the majority of their time in physical therapy on retraining walking, and cite recovery of walking as a primary rehabilitation goal. assessment of walking using reliable and valid tools is a recommended practice in stroke rehabilitation guidelines in canada, the united states, australia, and the netherlands. the 10-metre walk test (10mwt) and the 6-minute walk test (6mwt) are highly recommended in guidelines and by professional organizations for the clinical evaluation of walking across the care continuum. for the 10mwt, the time to traverse the middle 10 metres of a 14-metre walkway at a comfortable pace is used to compute comfortable walking speed. for the 6mwt, the maximum distance achieved walking back and forth along a 30-metre walkway in six minutes is documented. to facilitate physical therapists' (pts') use of an evidence-informed approach to administering these walking tests post-stroke in an acute care, inpatient rehabilitation, or outpatient rehabilitation setting, the iwalk toolkit, a theory-based toolkit, was developed. this toolkit consists of an educational guide, a smartphone app, and an educational video. in this mixed methods study, pts across multiple sites were evaluated before and after a 5-month intervention involving the implementation of the iwalk toolkit. objectives of this study were: (1) to determine the nature and extent to which pts across the care continuum uptake/use information in a theory-based toolkit designed to guide use of the 10-metre and 6-minute walk tests post-stroke for initial assessment, goal setting, education, treatment selection and monitoring change; and (2) to describe pts' perceptions of the features of the guide, the provider and the setting that facilitated or prevented walk test administration and use of test scores for initial assessment, prognosis, goal setting, treatment selection and monitoring change.


Eligibility criteria:
inclusion criteria: * physical therapists working in hospitals providing acute care, in-patient rehabilitation, or outpatient rehabilitation services for people with stroke * physical therapists registered with the provincial regulatory body * physical therapists who provided walking rehabilitation to 10 or more patients with stroke per year * individuals in a professional leader (pl) or professional practice leader (ppl) role defined as an individual who was responsible for facilitating and advancing evidence-based physical therapy practice and ensuring that professional practice standards were met.
immediate effect of kinesiological taping

Conditions: Hemiplegia

Summary: in this study, it is aimed to examine the immediate effect of kinesiological taping on functionality in hemiplegic patients. 40 hemiplegic patients with a mean age of 63±15 years were included to the study. the patients were divided into two groups using the computerized randomization method. kinesiology tape was applied to the 1st group (study group), and a patch tape was applied to the 2nd group (control group). the demographic and physical characteristics of the people who agreed to participate in the study were recorded. in both groups; before taping, right after taping, 45 min. after and 4 days after taping timed get up and go test (tug) were administered. both groups were asked not to remove the tapes at the end of the 4th day.


Eligibility criteria:
inclusion criteria: * agree to participate in the study after detailed information about the study, * to have sufficient cognitive functions, to be diagnosed with hemiplegia by a specialist physician, * to be 18 years of age or older exclusion criteria: * diagnosis of other neurological diseases (parkinson's, multiple sclerosis, etc.), * cancer other than hemiplegia, heart failure, surgery in the area to be applied, * vascular problems in the lower extremity, * chronic kidney failure, * infection.

Keywords: hemiplegia kinesiology taping functionality
tislelizumab or tislelizumab combined with lenvatinib neo-adjuvant treatment for resectable rhcc

Conditions: Recurrent Hepatocellular Carcinoma

Summary: this non-randomized phase ii clinical trial aimed to explore the efficacy and safety of tislelizumab or tislelizumab combined with lenvatinib as neoadjuvant treatment for resectable rhcc patients

hepatocellular carcinoma (hcc) patients have about 70% of 5-year recurrence rate after curative treatment. only 30% of recurrent hcc (rhcc) patients are resectable when diagnosed. neoadjuvant treatment may reduce tumor burden and recurrence rate after surgery for rhcc patients. immune checkpoint inhibitors combined with or without antiangiogenic agents have already been reported effective in advanced hcc patients as first-line therapy, and in several early-stage solid tumors as neoadjuvant therapy. according to several preclinical results, immune infiltration and the expression of pd-1 were higher in rhcc tumors than in paired primary tumors. so, immune checkpoint inhibitors combined with or without antiangiogenic agents might have a better response in rhcc patients than primary hcc patients. herein, we designed this phase ii clinical trial to explore the efficacy and safety of tislelizumab (pd-1 inhibitor) or tislelizumab combined with lenvatinib as neoadjuvant treatment for resectable rhcc patients. enrolled resectable rhcc patients will be divided into two non-randomized seperate arms, sequentially (arm 1: neoadjuvant tislelizumab; arm 2: neoadjuvant tislelizumab and lenvatinib). each arm was estimated to enroll 40 patients. we have already enrolled 17 patients in arm 1, and have terminated the enrollment of arm 1 due to modest treatment responses. the enrollment of arm 2 is ongoing.

Eligibility criteria:
inclusion criteria: 1. diagnosed as recurrent hepatocellular carcinoma after curative treatment; 2. the criteria for resectability is met; 3. has at least one evaluable lesion according to the recist 1.1 standard and has not received local treatment; 4. eastern cooperative oncology group score 0-1, child-pugh score 5-7; 5. agree to biopsy and blood sample collection; 6. adequate organ and marrow function. exclusion criteria: 1. previously received any transarterial chemoembolization and immune therapy and other local or systemic liver cancer treatments, except for curative ablation; 2. extrahepatic metastasis; 3. history of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding; 4. history of autoimmune disease or need to take immunosuppressant drugs for a long time; 5. history of testing positive for human immunodeficiency virus (hiv) or known acquired immunodeficiency syndrome (aids); 6. abnormal organ function

Keywords: recurrent hepatocellular carcinoma neoadjuvant treatment immune therapy
efficacy comparative study between tears again®, opticol® and optive®

Conditions: Dry Eye Syndrome

Summary: primary purpose: * to compare the efficacy in treating dry eye syndrome in contact lens wearers or computer users of tears again® versus opticol® versus optive® secondary purpose: * subjective evaluation of symptomatology * evaluation of preference in different kind of administration - spray versus monodoses versus multi-doses


Eligibility criteria:
inclusion criteria: * informed consent signed * age \>18 years and \< 55 years * daily wearer of soft contact lens and/or daily (\> 4 hours/day) computer user exclusion criteria: * dry eye syndrome other than of evaporative etiology, according to dews * ocular or systemic disease that can affect the normal tear film * pregnancy or pregnancy risk (no contraceptive method), lactation
effect of virtual endoscopy simulator training on real patient endoscopy

Conditions: Pain

Summary: trainees (residents in internal medicine), naive to real patient endoscopy, will be randomized to receive either 3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator gi-mentor or no training before starting on-patient endoscopy in the university of vienna medical school endoscopy unit. patients satisfaction and pain, technical accuracy and number of found/missed pathologies as well as average time for successful endoscopy will be recorded. after one month or 50 supervised, self performed endoscopies, trainees will be evaluated again with the above mentioned criteria during ten consecutive investigations.


Eligibility criteria:
inclusion criteria: * trainees: naive to real patient endoscopy before training phase exclusion criteria: * medical doctors with experience in gastrointestinal endoscopy * patients sedated for upper gi endoscopy * patients unwilling or unable to sign informed consent

Keywords: training patient satisfaction endoscopy simulator safety
the efficacy and safety of sugammadex in children 0-2 years old

Conditions: Anesthesia; Pediatric Cancer; Pediatric Tumor; Pediatric Hepatoblastoma; Beta-Thalassemia; Hepatic Metastases

Summary: sugammadex is a selective antidote to muscle relaxants rocuronium bromide and vecuronium bromide. sugammadex is a modified gamma-cyclodextrin, a compound that selectively binds rocuronium bromide and vecuronium bromide. it forms a complex with them in the blood plasma, which leads to the decrease in the concentration of muscle relaxant binding to nicotinic receptors in the neuromuscular synapse. the result is the the elimination of neuromuscular blockade caused by rocuronium bromide or vecuronium bromide. sugammadex is used to eliminate neuromuscular blockade caused by rocuronium bromide in children aged 2 years and adolescents in standard clinical situations. the aim of the study is to prove the efficacy and safety of sugammadex in children under 2 years

nowadays muscle relaxants are widely used in pediatric practice, but their use is fraught with numerous risks and complications. the main ones are the residual neuromuscular block and the possibility of developing a recurrence in the patient. in connection with this, the development and introduction into practical anesthesiology of new, more effective drugs for arresting the action of muscle relaxants is still relevant. one of the them, sugammadex was recently introduced into clinical practice and provided a fundamentally new approach to the recovery of neuromuscular conduction. often, children under two years of age need general anesthesia for mri (prolonged stay in the device, apnea to get a high-quality image without respiratory artifacts, severe pain syndrome, severe neurological deficit, etc.). the aim of the study is the evaluation of the efficacy of sugammadex, estimated by restoring neuromuscular conduction within 0-120 seconds after bolus administration, and the safety and tolerability of sugammadex in children under two years of age. children will be observed in the hospital during 24 hours. a group of patients from 2 to 18 years of age, in whom the drug sugammadex is used as standard therapy will be taken as a comparison group .

Eligibility criteria:
inclusion criteria: * children 0 to 2 years (0 - 24 months, inclusive) in the study group; children from 2 to 18 years in the comparison group (control group) * patients with malignant neoplasms of the liver, malignant neoplasms with metastatic liver damage, beta-thalassemia * informed consent of the patient and / or parents or trustee of the patient exclusion criteria: * kidney failure * liver failure * critical conditions * septicemia * severe and decompensated diseases of the cardiovascular system * refusal of the patient and / or his parents or trustee to participate in the study.

Keywords: anesthesia pediatrics pediatric oncology mri anesthesia
use of monitorme in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: monitorme is a telephone device intended for the non-critical monitoring of vital signs in a domestic environment with the ability to automatically transmit data to a remote location via basic telephone connectivity. monitorme's low-cost, call automation and simple to use technology (i.e. based on the principles of an ordinary plug-in telephone) make it appropriate for a wide number of care pathways. it eliminates the need for a modem or broadband and avoids the challenges of less reliable smart phone technology. typical use scenarios include remote monitoring of individual or multiple chronic disease states such as copd to improve patient outcomes including prevention of emergency admissions. there is growing interest in the use of home telemonitoring in copd in order to facilitate the management of the increasing numbers of patients and pressures on the nhs. despite the positive effects of telemonitoring in conditions such as heart failure, benefits remain unproven in copd and further work is required before wide-scale use. furthermore, until now the evaluation of telecare and telehealth developments has focused mainly on effectiveness and efficiency, whereas their social, and ethical implications in particular, have not been explored in depth. we will also explore ethical issues related to the use of telehealth systems, from both the patients' and the healthcare professionals' perspective. the current feasibility study is designed to assess the acceptability, usability and validity of monitorme within one of its intended purposes i.e. remote monitoring of individual or multiple chronic disease states such as copd.


Eligibility criteria:
inclusion criteria: patients * adults diagnosed with any severity of copd (according to british thoracic society criteria, i.e. \>10 pack year smoking history and post bronchodilator spirometry fev1/fvc ratio \<0.70 and fev\<80%) * listed on referral lists or copd registers within lincolnshire community health services nhs trust or nhs south west lincolnshire ccg health care professionals * involved in implementing the device within lincolnshire community health services nhs trust or nhs south west lincolnshire ccg * provide informed consent to participate in an interview exclusion criteria: patients * inability or unwillingness to sign informed consent * no active telephone line in home * copd exacerbation within the previous 6 weeks. * mental health, cognitive or neurological conditions that would make study participation inappropriate * life expectancy \< 6 months * implanted pacemaker * hearing or visual ailments that would preclude the use of the monitorme device * inability to use both hands (i.e. hold handset in one hand and use keypad with the other at same time) * inability to understand verbal english health care professionals * not involved in implementing the device within lincolnshire community health services nhs trust or nhs south west lincolnshire ccg * unable/unwilling informed consent to participate in an interview

Keywords: telehealth telemonitoring copd
pilot study of erlotinib for the treatment of patients with de novo acute myeloid leukemia

Conditions: Leukemia, Myelomonocytic, Acute

Summary: this research study is looking for patients with newly diagnosed acute myeloid leukemia (aml), aml that has returned (relapsed), or it has not responded adequately to previous treatments. treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. the purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their aml.


Eligibility criteria:
inclusion criteria: * diagnosis of aml with no history of previous clonal/malignant hematologic disorders such as myelodysplastic syndromes or myeloproliferative disorders. * newly diagnosed patients will be age 70 or older * relapses patients will be age 60 or older any time following first relapse, if patient is not considered candidate/not interested in salvage chemotherapy. * refractory disease patients will be age 18-59 who have failed at least 2 lines of conventional chemotherapy (1 induction and 1 salvage) * patient must have discontinued all previous therapies for aml at least 14 days and recovered from the non-hematologic side effects of the therapy. * laboratory tests must be within protocol-specified ranges * patient must be able to swallow and tolerate oral medication. exclusion criteria: * patients with known central nervous system (cns) leukemia by spinal fluid cytology, flow cytometry or imaging. * history of antecedent pre-leukemic hematologic disorders such as myelodysplastic syndromes or myeloproliferative disorders. * diagnosis of acute promyelocytic leukemia (apl) * patients who require chronic anticoagulation, are current smokers or who are taking rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and st. john's wort are not eligible. * patients with active corneal erosions or history of abnormal corneal sensitivity test. * patients with serious illness such as: significant ongoing or active infection, new york heart association (nyha) grade ii or greater congestive heart failure, unstable angina (anginal symptoms at rest), new onset angina (began within the last 3 months), myocardial infarction within the past 6 months, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy, cerebrovascular accident within past 3 months, or psychiatric illness that would limit compliance with the study requirements.

Keywords: leukemia, myelomonocytic, acute erlotinib
affection of renal and urinary system in ibd patients

Conditions: Nephrolithiasis, Glomerulonephritis, Amyloidosis,AKI, CKD, Tubuli Interstitial; Urinary System Disorders in IBD Patients

Summary: detection and classification of different renal and urinary affection in patients with ibd that attended to assist university hospitals

background (research question, available data from the literature, current strategy for dealing with the problem, rationale of the research that paves the way to the aim(s) of the work). (200-250 words max.) inflammatory bowel disease is an idiopathic disease cause sever inflammation of git , presentes in ulcerative colitis or crohn's disease occur in 6%-47% ibd is profoundly associated with extra intestinal manifestions , especially renal and urinary involvement occurs in 4% - 23% of patients with ibd. patterns of renal complications include nephrolithiasis, glomerulonephritis, amyloidosis, akl, ckd, tubulointerstitial nephritis, asymptomatic proteinuria and hematuria; each type has specific mechanism nephrolithiasis is 10-100 times greater in ibd patients than general population.most common stones are calcium, oxalate and urate; stones occur due to loss of electrolytes "mg,k" due to diarrhea which lead to crystallization. glomerulonephritis pattern in ibd , is associated with iga nephropathy, igm nephropathy, membranous and focal segmental glomerulonephritis. there is genetic connection between iga nephropathy and intestinal diseases! secondary amyloidosis (aa-type) is a rare but serious complication of ibd.renal amyloidosis had been proven to be the most common lethal manifestion of ibd - associated amyloidosis (a), since renal involvement rapidly leads to end stage renal failure. sever long -standing ibd consists a predisposing factor for renal complications that occur in 4-23 % of patients so we aim to shed more light on the pathophysiology of renal damage in ibd; considering the renal manifestions and complications of ibd, it is important to emphasize the role of screening of renal function in preventing, diagnosing, and,if possible, reversing probable kidney damage.

Eligibility criteria:
inclusion criteria: * 100 patients suffering of ibd who attended to auh either with crohn's or ulcerative colitis with different presentation exclusion criteria: * patients with other known cause of kidney or urinary affection as dm,htn,apckd, lupus nephritis,uti.....
epidemiology of gonococcal arthritis (epgar)

Conditions: Gonococcal (GC) Infection; Arthritis, Infectious

Summary: the aim of this retrospective observational study was to describe the epidemiology of neisseria gonorrhoeae septic arthritis over the last 10 years at brest and rennes university hospitals. the main question is whether there are any risk factors based on the epidemiological and clinical data on these cases. the second objective is to characterize the gonococcal strains isolated in order to determine whether there is a common clone, a virulence factor or specific resistance genes.


Eligibility criteria:
inclusion criteria: * patients with a neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 2014 and 2024. exclusion criteria: * patients with neisseria gonorrhoeae-negative joint sample (from enrichment vial or native sample). * patients who have expressed opposition to inclusion in the study. * patients under legal protection (guardianship, curatorship, etc.).

Keywords: gonococcal arthritis
an immunonutritional approach to the prevention of skin cancer

Conditions: Skin Cancer

Summary: skin cancer incidence continues to rise and ultraviolet radiation (uvr) in sunlight is the principal cause. solar uvr can promote cancer development through its ability to suppress the immune system. the purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids can protect human skin from uvr-induced immunosuppression.

skin cancer is one of the most common human cancers with a rising incidence and considerable negative impact on human health. exposure to ultraviolet radiation (uvr) in sunlight is the major aetiological factor in skin cancer initiation and progression. human case-control studies have reported an inverse relationship between dietary fish or omega-3 polyunsaturated fatty acid (pufa) intake and occurrence of non-melanoma skin cancer. omega-3 pufa have the potential to reduce the risk of photocarcinogenesis primarily by their ability to reduce production of prostaglandin e2 and consequently photoimmunosuppression. to date, no studies have assessed the impact of omega-3 pufa on skin photoimmunosuppression in humans. objective: to examine the potential of dietary omega-3 pufa to protect against uvr-induced cutaneous immunosuppression in humans. study design: a double-blind randomised controlled nutritional study in 64 healthy human volunteers with nickel sensitivity. volunteers will receive 3 months dietary supplementation with either omega-3 pufa (n=32) or gelatine (n=32) both provided in identical gelatine capsules. the aim is to quantify the influence of omega-3 pufa on: 1. uvr-induced suppression of clinical contact hypersensitivity (chs) responses 2. uvr-induced modulation of epidermal langerhans cell trafficking 3. uvr-induced modulation of levels of immunoregulatory mediators

Eligibility criteria:
inclusion criteria: * pre-menopausal females * sun-reactive skin type i / ii * reporting allergy to jewellery with nickel content exclusion criteria: * history of atopy * history of skin cancer * history of a photosensitivity disorder * sunbathing (including sunbeds) in the last 3 months * pregnancy * history of cardiac disease * taking photoactive medicine * not able to eat fish or gelatine * taking fish oil supplements prior to the study

Keywords: immunosuppression ultraviolet radiation nickel contact hypersensitivity